[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594142":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":90,"collaborators":10,"id":93,"slug":10,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":10,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":10,"enrollmentInfo":101,"targetDuration":104,"studyType":105,"phases":10,"briefSummary":106,"conditions":107,"keywords":10,"overallStatus":111,"whyStopped":10,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental group",null,"780 patients for interview",[13],"Other: interview",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"interview","30 for Qualitative interview and 750 for quantitative survey",[9],[20],{"name":21,"affiliation":5,"role":22},"Gang Chen, PhD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Gang Chen","CONTACT","086-027-83662681","tjchengang@hust.edu.cn",[30,47,62,77],{"facility":31,"status":10,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Ying Zhou","Hefei","Anhui","230001","China",{"type":37,"coordinates":38},"Point",[39,40],117.28083,31.86389,{"lat":40,"lon":39},[43],{"name":44,"role":26,"phone":45,"phoneExt":10,"email":46},"Ying Zhou, PhD","13865901025","caddie1234@gmail.com",{"facility":48,"status":10,"city":49,"state":50,"zip":51,"country":35,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Shuzhong Yao","Guangzhou","Guangdong","510080",{"type":37,"coordinates":53},[54,55],113.25,23.11667,{"lat":55,"lon":54},[58],{"name":59,"role":26,"phone":60,"phoneExt":10,"email":61},"Shuzhong Yao, ph.D","086-020-87755766","yszlfy@163.com",{"facility":25,"status":10,"city":63,"state":64,"zip":65,"country":35,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Wuhan","Hubei","430030",{"type":37,"coordinates":67},[68,69],114.26667,30.58333,{"lat":69,"lon":68},[72,73,76],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":74,"role":26,"phone":27,"phoneExt":10,"email":75},"Yingjie Hu","huyj@hust.edu.cn",{"name":25,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":78,"status":10,"city":79,"state":10,"zip":65,"country":35,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Dongling Zou","Chongqing",{"type":37,"coordinates":81},[82,83],106.55771,29.56026,{"lat":83,"lon":82},[86],{"name":87,"role":26,"phone":88,"phoneExt":10,"email":89},"Dongling Zou, ph.D","086-023-65301682","cqzl_zdl@163.com",{"type":22,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Gang Chen (101199)","Prof","100594142",false,"NCT07015593","Patient Journey in Advanced Gynecologic Cancers","Patient Journey in Conventional Therapy for Primarily Treated Advanced Gynecologic Cancers in China","Inclusion Criteria:\n\n* Age 18 or older\n* Newly diagnosed stage III or IV CC or EC\n* Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis.\n* Told by their physician that their disease is stable.\n* Patients must have informed consent form (ICF) signed for the study.\n\nExclusion Criteria:\n\n* Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.\n* Previously participated in or participating in a clinical trial.\n* Patients who received another line of therapy after initial therapy.\n* Unable or unwilling to provide informed consent.\n* Not fluent in local language.\n* Indicates or exhibits hearing difficulties, which would make a conversation challenging.","FEMALE","18 Years",{"count":102,"type":103},780,"ESTIMATED","1 Day","OBSERVATIONAL","This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.",[108,109,110],"Genital Neoplasms, Female","Uterine Cervical Neoplasms","Endometrial Carcinoma","NOT_YET_RECRUITING","2025-06-04",{"date":114,"type":115},"2025-06-11","ACTUAL",{"date":117,"type":103},"2025-07-01",{"date":119,"type":103},"2026-11-30",{"name":5,"class":6},4]